FGF21-PKE Adnectin (Bristol-Myers Squibb)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameFGF21-PKE Adnectin (Bristol-Myers Squibb)
Drug Alias NameFGF21-adPKE
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionFibroblast growth factor 21 modulators
TargetsFibroblast growth factor 21
Therapy Area/IndicationsMetabolic Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsMetabolic Diseases

Other Information

ATC CodeN/A
Related LinksN/A